Is PepGen (PEPG) One of the Best NASDAQ Stocks Under $5 to Buy Right Now?

PepGen Inc. (NASDAQ:PEPG) is one of the best NASDAQ stocks under $5 to buy right now. On May 12, PepGen reported Q1 2026 financial results, recording a net loss of $17.8 million, or $0.26 per share, compared to a net loss of $30.2 million for Q1 2025. R&D expenses decreased to $13.0 million, down from $25.4 million in the prior year’s Q1, while G&A expenses held steady at $5.9 million. The company concluded the quarter with $132.3 million in cash, cash equivalents, and marketable securities, which it expects will provide a sufficient capital runway to fund operations into H2 2027.

On the clinical front, PepGen achieved full enrollment for the 10 mg/kg cohort of its Phase 2 FREEDOM2-DM1 multiple ascending dose trial for PGN-EDODM1, an investigational oligonucleotide therapy for myotonic dystrophy type 1. Topline results from the initial 5 mg/kg cohort showed a favorable safety profile alongside promising splicing and clinical data, supporting ongoing dose escalation. Data from the 10 mg/kg cohort remains on track for release in H2 2026, while the subsequent 12.5 mg/kg cohort data is anticipated in 2027.

Is PepGen (PEPG) One of the Best NASDAQ Stocks Under $5 to Buy Right Now?

Regulatory expansions continue with clearance to initiate the FREEDOM2 trial in South Korea, Australia, and New Zealand, alongside active clinical sites in Canada and the UK. Meanwhile, the US FDA placed a partial clinical hold on the study regarding historical preclinical pharmacology and toxicology data. PepGen Inc. (NASDAQ:PEPG) is working to resolve the agency’s inquiries and noted that the timeline for the ongoing clinical study has not been impacted.

PepGen Inc. (NASDAQ:PEPG) is a clinical-stage biotech company using its proprietary Enhanced Delivery Oligonucleotide/EDO platform to develop therapies for severe neuromuscular and neurological diseases. By using cell-penetrating peptides to improve therapeutic uptake, the company aims to target the root causes of these serious conditions.

While we acknowledge the risk and potential of PEPG as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PEPG and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1